Drugs / AK119
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05173792 | Dec 2021 → May 2023 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1 | NCT04572152 | Dec 2020 → May 2023 | — | Akeso | Completed | No outcome recorded |
| Phase 1 | NCT04516564 | Sep 2020 → May 2021 | COVID-19 | Akeso Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05846867 | May 2023 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05689853 | Apr 2023 → Dec 2026 expected | cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05636267 | Feb 2023 → Feb 2025 | non-small cell lung carcinoma | Akeso | Terminated | No outcome recorded |
| Phase 1/2 | NCT05559541 | Dec 2022 → May 2024 | cancer | Akeso | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05559541 ↗ |
| Action | Inhibit | “anti-CD73” NCT05689853 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody targeting the CD73” NCT04516564 ↗ |
| Route | Intravenous | “Single dose of AK119 is administered via intravenous infusion to healthy subjects” NCT04516564 ↗ |